CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Godói, Isabella Piassi Dias; Lemos, Larissa de Araújo; Araújo, Vânia Eloísa de; Bonoto, Braúlio Cesar; Godman, Brian; Júnior, Augusto Afonso Guerra

doi:10.2217/cer-2016-0045

Cited by 47 publications

(32 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering that the first dengue vaccine approved in the country (Dengvaxia ® ) has a different efficacy for each serotype [28], it could be important to evaluate the dengue seroprevalence in the country. In this context, it is important to develop a National Seroprevalence Study for dengue to better inform future policy decision making if this does not already exist.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Godói

Silva

Sarker

et al. 2018

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Currently, there is no specific antiviral treatment to manage the dengue virus [23][24][25][26]. At the end of 2015, the Brazilian Government approved the first dengue vaccine (CYD-TDV; Dengvaxia ® ) to prevent DENV infection with a reported global efficacy of 60%, recommended for individuals between 9 and 45 years old [27,28].…”

Section: Introductionmentioning

confidence: 99%

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Godói

Silva

Sarker

et al. 2018

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…The recent introduction of dengue vaccines make understanding severe dengue more important as these vaccines may promote severe disease in certain subpopulations 50 . An improved understanding of dengue and its dynamic circulation are required for successful public health policies and vaccination programs.…”

Section: Discussionmentioning

confidence: 99%

The reintroduction of DENV-2 in 2011 in Panama and subsequent outbreak characteristic

et al. 2018

View full text Add to dashboard Cite

The circulation of the South-east Asian/American (AS/AM) dengue 2 virus (DENV-2) genotype in the Americas has been associated with a high rate of severe disease. From 1993, the year DENV was reintroduced in Panama, until 2011 there were 29 dengue-associated deaths, 17 of which occurred in 2011, the most severe outbreak with a case fatality rate (CFR) of 44% (17 deaths out of 38 severe dengue cases). During this outbreak DENV-2 was reintroduced into the country, whereas over the prior five years DENV-1 and −3 were predominant. Herein, we describe the 2011 Panama outbreak and genetically characterize the Panamanian DENV-2 strains, which were associated with severe dengue disease in Panama. Our results suggest that the DENV-2 isolates from this outbreak belonged to the AS/AM genotype sub-clade 2BI and were genetically close to viruses described in the outbreaks in Nicaragua, Honduras, Guatemala and Mexico from 2006–2011. Sub-clade 2BI has previously been associated with severe disease in Nicaragua during outbreaks from 2005–2007.

show abstract

“…Subsequently, factors such as increased international freight and travel, urbanization, and vector control strategies and tools poorly suited to urban environments or hampered by insecticide resistance [ 119 ] have resulted in the global explosion of dengue. Yellow fever outbreaks can be prevented or controlled by mass vaccine distribution [ 120 ], but no vaccines are available for chikungunya and Zika, and the licensed dengue vaccine offers incomplete and serotype-specific protection [ 121 ]. Consequently, outbreak prevention and response remain reliant on vector control.…”

Section: Vector Surveillance and Control Of Aedes mentioning

confidence: 99%

Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats

Weetman

Kamgang

Badolo

et al. 2018

IJERPH

196

203

View full text Add to dashboard Cite

The Zika crisis drew attention to the long-overlooked problem of arboviruses transmitted by Aedes mosquitoes in Africa. Yellow fever, dengue, chikungunya and Zika are poorly controlled in Africa and often go unrecognized. However, to combat these diseases, both in Africa and worldwide, it is crucial that this situation changes. Here, we review available data on the distribution of each disease in Africa, their Aedes vectors, transmission potential, and challenges and opportunities for Aedes control. Data on disease and vector ranges are sparse, and consequently maps of risk are uncertain. Issues such as genetic and ecological diversity, and opportunities for integration with malaria control, are primarily African; others such as ever-increasing urbanization, insecticide resistance and lack of evidence for most control-interventions reflect problems throughout the tropics. We identify key knowledge gaps and future research areas, and in particular, highlight the need to improve knowledge of the distributions of disease and major vectors, insecticide resistance, and to develop specific plans and capacity for arboviral disease surveillance, prevention and outbreak responses.

show abstract

CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Abstract: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

Cited by 47 publications

References 43 publications

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

The reintroduction of DENV-2 in 2011 in Panama and subsequent outbreak characteristic

Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats

Contact Info

Product

Resources

About